Bactest was a venture-backed company based in Cambridge, UK, specialising in turning microbial activity into data for making management and operational decisions. Bactest ceased trading in 2018.
Bactest was founded to commercialise IP based on its technology platform, CYTOMAIA. Bactest has a patent portfolio of ten patents, some granted, some pending, and has plans to file further IP to protect its product lines.
Bactest's IP is centred around measuring and monitoring microbial activity, turning that activity into data and knowledge that enable its customers to make management and operational decisions that save time, carbon footprint and energy.